Prostate cancer is one of the most common cancers affecting men worldwide. In recent years, advanced hormone-targeting medicines such as Enzalutamide and Abiraterone have significantly improved treatment outcomes for patients with advanced and metastatic prostate cancer. While both medicines target the androgen (male hormone) pathway that fuels prostate cancer growth, they work differently and may be suitable for different patients.
